ReviewInternational journal of molecular sciences2024
The Pathophysiology and Treatment of Pyoderma Gangrenosum-Current Options and New Perspectives.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- Efficacy and safety of spesolimab in resistant pyoderma gangrenosum: a case report and brief review of the literature.Skin health and disease · 2026Article
- Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study.Dermatology and therapy · 2026Article
- Pyoderma Gangrenosum Masquerading as Chronic Infective Ulcers: Two Case Reports Across Age Extremes.Clinical case reports · 2026Article
- Integrative Multi-Omics Analysis and Computational Modeling Identifying Shared Inflammatory Pathways and JAK Inhibitor Targets in PG and IBD.International journal of molecular sciences · 2026Article
- Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update.Inflammatory bowel diseases · 2026Review
- Pyoderma gangrenosum following joint arthroplasty: a comprehensive review of clinical features, diagnosis, and management.Postepy dermatologii i alergologii · 2026Review
- Achieving Steroid-Sparing Remission in Refractory Pyoderma Gangrenosum With an Integrative Meta-Therapeutic System Based on Traditionally Engineered Nanomercury Sulfide: A Case Series.Case reports in dermatological medicine · 2026Article
- Successful treatment of severe retroauricular pyoderma gangrenosum with upadacitinib in a patient with Crohn's disease and a history of cerebral venous sinus thrombosis.Therapeutic advances in gastroenterology · 2026Article
- Article
- A Rare Case of Pyoderma Gangrenosum as a Complication of Ulcerative Colitis: A Case Report and Literature Review.Clinical case reports · 2025Article
- Penile Pyoderma Gangrenosum: A Rare Presentation and Review of Management Strategies: Case Report.Clinical case reports · 2025Article
- Pyoderma gangrenosum associated with major adverse cardiovascular events.JEADV clinical practice · 2025Article
- Pyoderma gangrenosum treated with oral abrocitinib in a 54-year-old woman: A case report.JAAD case reports · 2025Article
- Upadacitinib for ulcerative colitis and pyoderma gangrenosum in a patient with schizophrenia on long-term risperidone: A case report.World journal of gastroenterology · 2025Article
- Disrupted Redox Regulation and Inflammatory Response in Pyoderma Gangrenosum.Life (Basel, Switzerland) · 2025Article
- Unveiling the Uncommon: Pyoderma Gangrenosum as an Extraintestinal Complication of Ulcerative Colitis.ACG case reports journal · 2025Article
- Pyoderma Gangrenosum in a Patient with Crohn's Disease Treated with Adalimumab: A Case-Based Review and Systematic Review of the Current Literature.Clinics and practice · 2025Review
- Paraneoplastic Dermatoses: A Clue for Underlying Malignancies.Journal of clinical medicine · 2025Review
- [Postoperatively developing ulcerous skin lesions with associated ulcerative colitis in a patient with status after femorocrural (P3) bypass insertion for peripheral arterial occlusion disease].Chirurgie (Heidelberg, Germany) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Pyoderma gangrenosum (PG) is an uncommon inflammatory dermatological disorder characterized by painful ulcers that quickly spread peripherally. The pathophysiology of PG is not fully understood; however, it is most commonly considered a disease in the spectrum of neutrophilic dermatoses. The treatment of PG remains challenging due to the lack of generally accepted therapeutic guidelines. Existing therapeutic methods focus on limiting inflammation through the use of immunosuppressive and immunomodulatory therapies. Recently, several reports have indicated the successful use of biologic drugs and small molecules administered for coexisting diseases, resulting in ulcer healing. In this review, we summarize the discoveries regarding the pathophysiology of PG and present treatment options to raise awareness and improve the management of this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.